At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed May 12, 2026 at 07:35 ET
MiNK Therapeutics presented data at ASGCT 2026 showing its off-the-shelf iNKT cell therapy, agenT-797, produced context-dependent immune responses (pro-inflammatory in cancer, anti-inflammatory in ARDS) from the same manufacturing batch without genetic engineering. The data supports advancement into a randomized Phase 2 trial in acute lung injury, with preliminary results expected in 2026.
- agenT-797 drove TH1 pro-inflammatory immune program in 34 solid tumor patients and TH2 anti-inflammatory response in 20 ARDS patients from the same donor batch.
- Data includes complete metastatic remission in germ cell testicular cancer (agenT-797 + anti-PD-1) and improved survival/pathogen clearance in severe ARDS.
- Favorable safety profile: no uncontrolled cytokine release syndrome or pathologic hyperinflammation.
- Company advancing to randomized Phase 2 trial in acute lung injury (C-1300-02) with preliminary data expected in 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access